Vivos Inc. (RDGL) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Vivos Inc. (RDGL) Healthcare & Pipeline Overview

Vivos Inc. develops innovative brachytherapy devices, including RadioGel and IsoPet, targeting non-resectable tumors in humans and animals. With a focus on precision radionuclide therapy, Vivos operates in the competitive medical device sector, facing challenges in a market dominated by larger, established players.

What Is the Investment Thesis for RDGL?

Vivos Inc. presents a high-risk, high-reward investment opportunity within the medical device sector. The company's focus on precision radionuclide therapy, particularly with its RadioGel and IsoPet products, addresses a growing need for targeted cancer treatments. A key value driver is the potential for regulatory approval and commercialization of these innovative therapies. However, the company's negative gross margin of -127.4% and ROE of -178.3% indicate significant financial challenges. The company's small market capitalization of $26.5M and negative free cash flow of $-0.00 billion highlight the need for substantial capital investment to support ongoing research, development, and commercialization efforts. Success hinges on clinical trial outcomes, regulatory approvals, and the ability to secure funding to sustain operations and expand market reach. The beta of -0.64 suggests a lower correlation with the overall market, but the company's financial instability introduces substantial risk.

Based on FMP financials and quantitative analysis

RDGL Key Highlights

Market Cap of $26.5M reflects the company's small size and potential for high growth, but also indicates higher risk.

• Gross Margin of -127.4% indicates significant challenges in profitability and cost management.
• ROE of -178.3% highlights the company's current financial instability and the need for improved efficiency.
• Free Cash Flow of $-0.00 billion demonstrates the company's reliance on external funding to support operations.
• Beta of -0.64 suggests a lower correlation with the overall market, potentially offering diversification benefits, but also reflecting the company's unique risk profile.

Who Are RDGL's Competitors?

RDGL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are RDGL's Key Strengths?

Innovative technology in precision radionuclide therapy.

• Potential for targeted cancer treatment with minimal side effects.
• Focus on both human and animal health applications.
• Proprietary formulations and patents.

What Are RDGL's Weaknesses?

Limited financial resources and negative profitability.

• Small market capitalization and reliance on external funding.
• Dependence on regulatory approvals for product commercialization.
• Limited market presence and brand recognition.

What Could Drive RDGL Stock Higher?

Clinical trial results for RadioGel in treating specific cancer types.

• Regulatory approval decisions for RadioGel and IsoPet.
• Development and commercialization of the yttrium-90 based device.
• Strategic partnerships and acquisitions to expand product portfolio and market reach.

What Are the Key Risks for RDGL?

Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.

• Failure to obtain regulatory approvals for its products.
• Competition from larger, more established companies.
• Inability to secure sufficient funding to support operations.
• Negative gross margin and financial instability.
• Dependence on key personnel and intellectual property.

What Are the Growth Opportunities for RDGL?

• Expansion of RadioGel Applications: RadioGel, Vivos Inc.'s injectable particle-gel, holds potential for treating a variety of non-resectable tumors in both humans and animals. The market for targeted radiation therapies is growing, driven by the desire to minimize damage to healthy tissue. Expanding clinical trials to demonstrate efficacy across different cancer types could significantly increase market adoption. The timeline for this growth opportunity depends on clinical trial results and regulatory approvals, potentially leading to increased revenue streams within the next 3-5 years.
• Commercialization of IsoPet: IsoPet offers a targeted radiation therapy solution for solid tumors in animals, addressing a growing market for veterinary oncology. As pet ownership increases and owners are willing to invest more in their pets' healthcare, the demand for advanced cancer treatments for animals is rising. Successful commercialization of IsoPet could establish Vivos Inc. as a key player in the veterinary oncology market. This growth opportunity could materialize within the next 2-3 years with effective marketing and distribution strategies.
• Development of Yttrium-90 Based Device: Vivos Inc.'s development of an yttrium-90 based precision radionuclide therapy device represents a significant growth opportunity. Yttrium-90 is a widely used radioisotope in cancer treatment, and a device specifically designed for precision delivery could offer advantages over existing methods. The timeline for this growth opportunity depends on successful device development, clinical trials, and regulatory approvals, potentially leading to market entry within the next 4-6 years.
• Strategic Partnerships and Acquisitions: Vivos Inc. could pursue strategic partnerships with larger medical device companies or research institutions to accelerate product development and commercialization. Collaborations could provide access to funding, expertise, and distribution networks, enhancing the company's competitive position. Acquisitions of complementary technologies or companies could also expand Vivos Inc.'s product portfolio and market reach. The timing and success of this growth opportunity are dependent on identifying suitable partners and executing successful deals.
• Expansion into International Markets: While currently focused on the United States, Vivos Inc. could expand its market reach by entering international markets. The demand for advanced cancer treatments is growing globally, and Vivos Inc.'s products could address unmet needs in various regions. International expansion would require navigating different regulatory landscapes and establishing distribution channels, but it could significantly increase the company's revenue potential. This growth opportunity could be pursued within the next 3-5 years, depending on regulatory approvals and market assessments.

What Threats Does RDGL Face?

• Competition from established players in the radiation oncology market.
• Regulatory hurdles and delays in product approvals.
• Technological advancements that could render existing products obsolete.
• Economic downturns that could reduce healthcare spending.

What Are RDGL's Competitive Advantages?

• Proprietary technology in precision radionuclide therapy.
• Patents protecting its RadioGel and IsoPet formulations.
• Specialized expertise in brachytherapy device development.
• Potential for strong relationships with key opinion leaders in oncology.

What Does RDGL Do?

Vivos Inc., formerly known as Advanced Medical Isotope Corporation, was founded in 1994 and rebranded in December 2017 to reflect its evolving focus on radiation oncology. The company is headquartered in Kennewick, Washington, and operates as a medical device company specializing in brachytherapy solutions. Vivos Inc. is dedicated to developing and commercializing innovative devices for the treatment of non-resectable tumors. Their primary product lines include RadioGel, an injectable particle-gel designed for Precision Radionuclide Therapy in both humans and animals, and IsoPet, a treatment option specifically for solid tumors in animals. Additionally, Vivos Inc. is developing an yttrium-90 based precision radionuclide therapy device, a universal laboratory cooling device, hydrogel, and other products under the Alpha-Gel, Beta-Gel, Gamma-Gel, and Precisiongel names. The company's focus is on providing targeted radiation therapy solutions that minimize damage to surrounding healthy tissue, improving treatment outcomes for patients with challenging tumors. Vivos Inc. aims to establish itself as a key player in the precision medicine space, offering advanced solutions for cancer treatment.

What Products and Services Does RDGL Offer?

• Develops brachytherapy devices for treating non-resectable tumors.
• Creates RadioGel, an injectable particle-gel for precision radionuclide therapy.
• Offers IsoPet for treating solid tumors in animals.
• Develops an yttrium-90 based precision radionuclide therapy device.
• Researches and develops hydrogel-based products under the Alpha-Gel, Beta-Gel, Gamma-Gel, and Precisiongel names.
• Focuses on precision medicine for targeted cancer treatment.

How Does RDGL Make Money?

• Develops and patents innovative medical devices for radiation oncology.
• Seeks regulatory approvals for its products from agencies like the FDA.
• Commercializes its products through direct sales or partnerships.
• Generates revenue from the sale of RadioGel, IsoPet, and future products.

What Industry Does RDGL Operate In?

Vivos Inc. operates within the medical device industry, specifically focusing on radiation oncology. The market for brachytherapy devices is driven by the increasing prevalence of cancer and the demand for minimally invasive treatment options. The competitive landscape includes established players like Elekta and Varian Medical Systems, as well as smaller companies developing innovative radiation therapy solutions. The industry is characterized by stringent regulatory requirements, long product development cycles, and the need for significant capital investment. Vivos Inc. aims to differentiate itself through its focus on precision radionuclide therapy and its injectable particle-gel technology, targeting a niche within the broader radiation oncology market.

Who Are RDGL's Key Customers?

• Hospitals and cancer treatment centers.
• Veterinary clinics and animal hospitals.
• Oncologists and radiation therapists.
• Patients with non-resectable tumors and their families.

Vivos Inc. Financial Trajectory

Vivos Inc. (RDGL) reported $36K in revenue for Q2 2026, reflecting 0.9% growth compared to the prior quarter. The company recorded a net loss of $830K, with diluted EPS of $-0.00. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company. Across the four most recent quarters, RDGL averaged $-0.00 in diluted EPS.

Company Profile

Vivos Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Kennewick, US. The company is led by CEO Michael K. Korenko. RDGL has traded publicly since 1998.

How Vivos Inc. Is Valued

Vivos Inc. carries a market capitalization of $26.5M, placing it in the micro-cap category. Relative to its peer group, RDGL's quantitative score of 61/100 is roughly in line with the peer average of 61/100.

Key Financial Metrics

Its free cash flow yield is -7.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 15.14 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -12.3%, the inverse of the P/E and a quick read on earnings relative to price.

Vivos Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 88.17 places it in the safe zone, indicating low near-term bankruptcy risk.

RDGL Financials

RDGL Latest News

RDGL Analyst Consensus

RDGL MoonshotScore

Vivos Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources